Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: The SANDS trial Academic Article uri icon

Overview

MeSH Major

  • Algorithms
  • Antihypertensive Agents
  • Blood Pressure
  • Diabetes Mellitus, Type 2
  • Hypertension

abstract

  • The Stop Atherosclerosis in Native Diabetics Study (SANDS) was a randomized open-label clinical trial in type 2 diabetics designed to examine the effects of intensive reduction of blood pressure, aggressive vs standard goals (< or =115/75 mm Hg vs < or =130/80 mm Hg), and low-density lipoprotein (LDL) cholesterol on the composite outcome of change in carotid intimal-medial thickness and cardiovascular events. The study demonstrated that in conjunction with a lower LDL cholesterol target of 70 mg/dL, aggressive systolic blood pressure-lowering resulted in a reduction in carotid intimal-medial thickness and left ventricular mass without measurable differences in cardiovascular events. The blood pressure treatment algorithm included renin-angiotensin system blockade, with other agents added if necessary. The authors conclude that both standard and more aggressive systolic blood pressure reduction can be achieved with excellent safety and good tolerability in patients with type 2 diabetes mellitus.

publication date

  • October 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4182961

Digital Object Identifier (DOI)

  • 10.1111/j.1751-7176.2009.00121.x

PubMed ID

  • 19817934

Additional Document Info

start page

  • 540

end page

  • 8

volume

  • 11

number

  • 10